7-碘-2,3-二氢苯并[b]呋喃 | 264617-03-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: 7-碘-2,3-二氢苯并[b]呋喃
• 英文名称: 2,3-dihydro-7-iodobenzofuran
• 英文别名: 7-Iodo-2,3-dihydrobenzo[b]furan；7-iodo-2,3-dihydro-1-benzofuran
• CAS: 264617-03-0
• 化学式: C₈H₇IO
• 分子量: 246.047
• InChiKey: IASDAJCCAFGOCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-碘-2,3-二氢苯并[b]呋喃 在 盐酸 、 四(三苯基膦)钯 、 无水硝酸铜 、 乙酸酐 、 sodium carbonate 、 三乙胺 、 tin(ll) chloride 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 30.0h， 生成 Phenyl N-[2,3-dihydro-7-(pyrid-3-yl)benzofuran-5-yl]carbamate
  参考文献：
  名称：

  Biarylcarbamoylindolines Are Novel and Selective 5-HT_2C Receptor Inverse Agonists:  Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent

  摘要：

  The evolution, synthesis, and biological activity of a novel series of 5-HT2C receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT2C affinity and selectivity over 5-HT2A receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT2B receptor. Compounds from this series are inverse agonists at the human cloned 5-HT2C receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.

  DOI：

  10.1021/jm990388c

文献信息

• [EN] ORGANIC COMPOUND, USE THEREOF AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME<br/>[FR] COMPOSÉ ORGANIQUE, SON UTILISATION ET DISPOSITIF ÉLECTROLUMINESCENT ORGANIQUE L'UTILISANT<br/>[ZH] 一种有机化合物和应用以及使用其的有机电致发光器件
  申请人：SHAANXI LIGHTE OPTOELECTRONICS MAT CO LTD

  公开号：WO2021136034A1

  公开（公告）日：2021-07-08

  一种具有式(1)所示结构的有机化合物，其中，Ar 1、Ar 2和Ar 3相同或不同，且各自独立地选自取代或未取代的碳原子数为6-30的芳基、取代或未取代的碳原子数为3-30的杂芳基、或者式(2)所示的结构，并且Ar 1、Ar 2和Ar 3中至少一者具有式(2)所示的结构；表示化学键。该有机化合物具有较高的热稳定性和玻璃化温度，将其作为有机电致发光器件的电子传输层材料时，可以提高器件的发光效率，延长器件的使用寿命。
• [EN] P2X7 MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR P2X7
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2014152604A1

  公开（公告）日：2014-09-25

  The present invention is directed to compounds of Formulas (I, la, lla and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, la, lla and IIb). Methods of making and using the compounds of Formulas (I, la, lla and IIb) are also within the scope of the invention.
• Biarylcarbamoylindolines Are Novel and Selective 5-HT_2C Receptor Inverse Agonists:  Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent
  作者：Steven M. Bromidge、Steven Dabbs、David T. Davies、Susannah Davies、D. Malcolm Duckworth、Ian T. Forbes、Laramie M. Gaster、Peter Ham、Graham E. Jones、Frank D. King、Keith R. Mulholland、Damian V. Saunders、Paul A. Wyman、Frank E. Blaney、Stephen E. Clarke、Thomas P. Blackburn、Vicky Holland、Guy A. Kennett、Sean Lightowler、Derek N. Middlemiss、Brenda Trail、Graham J. Riley、Martyn D. Wood

  DOI：10.1021/jm990388c

  日期：2000.3.1

  The evolution, synthesis, and biological activity of a novel series of 5-HT2C receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT2C affinity and selectivity over 5-HT2A receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT2B receptor. Compounds from this series are inverse agonists at the human cloned 5-HT2C receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.